Targeting ABCB5 for cancer therapy

Patent metadata

Field	Value
Publication number	US-9266946-B2
Application number	US-201414251932-A
Country	US
Kind code	B2
Filing date	Apr 14, 2014
Priority date	Apr 12, 2007
Publication date	Feb 23, 2016
Grant date	Feb 23, 2016

Abstract

The invention relates to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof.

First claim

What is claimed is:

1. A method for treating a subject, comprising
systemically administering an isolated antibody that selectively binds to ABCB5 to a subject having cancer in an effective amount to treat the cancer, wherein the isolated antibody is not co-administered with a chemotherapeutic agent.

2. The method of claim 1 , wherein the isolated antibody is a monoclonal antibody.

3. The method of claim 1 , wherein the isolated antibody has at least one human region.

4. The method of claim 1 , wherein the isolated antibody competitively inhibits binding of mAb 3C2-1D12 to ABCB5.

5. The method of claim 1 , wherein the isolated antibody is of immunoglobulin class IgA, IgGb 1, IgG2, IgG3, IgG4 or IgM.

6. The method of claim 1 , wherein the isolated antibody is a single chain antibody.

7. The method of claim 1 , wherein the subject has melanoma.

8. The method of claim 1 , wherein the subject is a human subject.

9. The method of claim 1 , wherein the subject is a companion animal.

10. The method of claim 1 , wherein the cancer is a cancer having cancer stem cells that express ABCB5 and is selected from the group consisting of biliary tract cancer; brain cancer; breast cancer; cervical cancer; choriocarcinoma; colon cancer; endometrial cancer; esophageal cancer; gastric cancer; intraepithelial neoplasms; lymphomas; liver cancer; lung cancer (e.g. small cell and non-small cell); neuroblastomas; oral cancer; ovarian cancer; pancreas cancer; prostate cancer; rectal cancer; sarcomas; skin cancer; testicular cancer; thyroid cancer; and renal cancer.

11. The method of claim 1 , further comprising, prior to the treatment of the subject detecting the presence of ABCB5 positive stem cells.

12. The method of claim 11 , wherein the presence of ABCB5 positive stem cells is detected by contacting a sample from a subject with a peptide that selectively binds to ABCB5 in order to detect cells that bind to the peptide.

13. The method of claim 12 , wherein the sample is a sample of a tumor mass.

Assignees

• Brigham & Womens Hospital

Inventors

• Frank Markus H
• Frank Natasha Y
• Sayegh Mohamed H

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• G01N33/575

  for cancer · CPC title